UF Innovate | Accelerate resident client NeXtGen Biologics has reported that the USPTO declined to initiate Inter Partes Review (“IPR”), following the filing by RegenX Science of two IPR Petitions in February 2025 requesting the cancellation of certain claims in NeXtGen’s US Patent Nos. 10,617,790 and 11,660,376, leaving the patents intact and fully enforceable. RegenX Science was formerly a licensee under these patents.
“True innovation to transform patient lives is at the heart of NeXtGen’s mission. Its patented NeoMatriX® Wound Matrix is a state-of-the-art solution for patients suffering from chronic and difficult to heal wounds,” said Jonelle Toothman, NeXtGen Biologics co-founder and CEO. “I want to thank Patent-Arts and the team at Duane Morris for their commitment to securing our technology for use in caring for patients.”
Read more about NeXtGen™ Biologics Secures Favorable Outcome in Inter-Partes Patent Review.
